{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:47:06Z","timestamp":1767192426684},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T00:00:00Z","timestamp":1609804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T00:00:00Z","timestamp":1609804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1245\/s10434-020-09464-9","type":"journal-article","created":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T17:07:57Z","timestamp":1609866477000},"page":"4637-4646","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Phase II Trial of Adjuvant Dendritic Cell Vaccine in Combination with Celecoxib, Interferon-\u03b1, and Rintatolimod in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases"],"prefix":"10.1245","volume":"28","author":[{"given":"Rajesh","family":"Ramanathan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haroon","family":"Choudry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Girgis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Gooding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawel","family":"Kalinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,5]]},"reference":[{"key":"9464_CR1","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1245\/s10434-013-3358-y","volume":"21","author":"D Magge","year":"2014","unstructured":"Magge D, Zenati MS, Austin F, et al. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol. 2014;21:1159\u201365. https:\/\/doi.org\/10.1245\/s10434-013-3358-y","journal-title":"Ann Surg Oncol."},{"key":"9464_CR2","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1245\/s10434-015-4838-z","volume":"23","author":"PM Polanco","year":"2016","unstructured":"Polanco PM, Ding Y, Knox JM, et al. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion in patients with high-grade, high-volume disseminated mucinous appendiceal neoplasms. Ann Surg Oncol. 2016;23:382\u201390. https:\/\/doi.org\/10.1245\/s10434-015-4838-z","journal-title":"Ann Surg Oncol."},{"key":"9464_CR3","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","volume":"15","author":"VJ Verwaal","year":"2008","unstructured":"Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15:2426\u201332. https:\/\/doi.org\/10.1245\/s10434-008-9966-2","journal-title":"Ann Surg Oncol."},{"key":"9464_CR4","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.1245\/s10434-013-3145-9","volume":"20","author":"AMJ Kuijpers","year":"2013","unstructured":"Kuijpers AMJ, Mirck B, Aalbers AGJ, et al. Cytoreduction and HIPEC in the Netherlands: nationwide long-term outcome following the Dutch protocol. Ann Surg Oncol. 2013;20:4224\u201330. https:\/\/doi.org\/10.1245\/s10434-013-3145-9","journal-title":"Ann Surg Oncol."},{"key":"9464_CR5","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/bjc.2014.419","volume":"111","author":"R Mirnezami","year":"2014","unstructured":"Mirnezami R, Mehta AM, Chandrakumaran K, et al. Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone. Br J Cancer. 2014;111:1500\u20138. https:\/\/doi.org\/10.1038\/bjc.2014.419","journal-title":"Br J Cancer."},{"key":"9464_CR6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411\u201322.","journal-title":"N Engl J Med."},{"key":"9464_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40425-016-0128-y","volume":"19","author":"M Radomski","year":"2016","unstructured":"Radomski M, Zeh HJ, Edington HD, et al. Prolonged intralymphatic delivery of dendritic cells through implantable lymphatic ports in patients with advanced cancer. J Immunother Cancer. 2016;19:24.","journal-title":"J Immunother Cancer."},{"key":"9464_CR8","doi-asserted-by":"publisher","first-page":"5934","DOI":"10.1158\/0008-5472.CAN-04-1261","volume":"64","author":"RB Mailliard","year":"2004","unstructured":"Mailliard RB, Wankowicz-Kalinska A, Cai Q, et al. Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized. Cancer Res. 2004;64:5934\u20137. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-1261","journal-title":"Cancer Res."},{"key":"9464_CR9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nprot.2017.130","volume":"13","author":"N Obermajer","year":"2018","unstructured":"Obermajer N, Urban J, Wieckowski E, et al. Promoting the accumulation of tumor-specific T cells in tumor tissues by dendritic cell vaccines and chemokine-modulating agents. Nat Protoc. 2018;13:335\u201357. https:\/\/doi.org\/10.1038\/nprot.2017.130","journal-title":"Nat Protoc."},{"key":"9464_CR10","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.4049\/jimmunol.164.9.4507","volume":"164","author":"PL Vieira","year":"2000","unstructured":"Vieira PL, de Jong EC, Wierenga EA, et al. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol. 2000;164:4507\u201312","journal-title":"J Immunol."},{"key":"9464_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/01.cji.0000211316.15278.6e","volume":"30","author":"A Wesa","year":"2007","unstructured":"Wesa A, Kalinski P, Kirkwood JM, et al. Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+\u2009T cell responses in vitro. J Immunother. 2007;30:75\u201382. https:\/\/doi.org\/10.1097\/01.cji.0000211316.15278.6e","journal-title":"J Immunother."},{"key":"9464_CR12","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s00262-008-0648-5","volume":"58","author":"AS Giermasz","year":"2009","unstructured":"Giermasz AS, Urban JA, Nakamura Y, et al. Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines. Cancer Immunol Immunother. 2009;58:1329\u201336. https:\/\/doi.org\/10.1007\/s00262-008-0648-5","journal-title":"Cancer Immunol Immunother."},{"key":"9464_CR13","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.smim.2010.03.002","volume":"22","author":"P Kalinski","year":"2010","unstructured":"Kalinski P, Okada H. Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors. Semin Immunol. 2010;22:173\u201382. https:\/\/doi.org\/10.1016\/j.smim.2010.03.002","journal-title":"Semin Immunol."},{"key":"9464_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/pros.21228","volume":"71","author":"E Wieckowski","year":"2011","unstructured":"Wieckowski E, Chatta GS, Mailliard RM, et al. Type-1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8(+) T cells against prostate cancer cells and defined prostate cancer-specific epitopes. Prostate. 2011;71:125\u201333. https:\/\/doi.org\/10.1002\/pros.21228","journal-title":"Prostate."},{"key":"9464_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1189\/jlb.1107737","volume":"84","author":"J-J Lee","year":"2008","unstructured":"Lee J-J, Foon KA, Mailliard RB, et al. Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia. J Leukoc Biol. 2008;84:319\u201325. https:\/\/doi.org\/10.1189\/jlb.1107737","journal-title":"J Leukoc Biol."},{"key":"9464_CR16","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1002\/eji.200323379","volume":"33","author":"PJ O\u2019Connell","year":"2003","unstructured":"O\u2019Connell PJ, Son Y-I, Giermasz A, et al. Type-1 polarized nature of mouse liver CD8alpha- and CD8alpha\u2009+\u2009dendritic cells: tissue-dependent differences offset CD8alpha-related dendritic cell heterogeneity. Eur J Immunol. 2003;33:2007\u201313. https:\/\/doi.org\/10.1002\/eji.200323379","journal-title":"Eur J Immunol."},{"key":"9464_CR17","doi-asserted-by":"publisher","first-page":"5972","DOI":"10.1158\/0008-5472.CAN-07-6818","volume":"68","author":"R Muthuswamy","year":"2008","unstructured":"Muthuswamy R, Urban J, Lee J-J, et al. Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res. 2008;68:5972\u20138. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-6818","journal-title":"Cancer Res."},{"key":"9464_CR18","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s00262-011-1015-5","volume":"60","author":"M Kato","year":"2011","unstructured":"Kato M, Nakamura Y, Suda T, et al. Enhanced anti-tumor immunity by superantigen-pulsed dendritic cells. Cancer Immunol Immunother. 2011;60:1029\u201338. https:\/\/doi.org\/10.1007\/s00262-011-1015-5","journal-title":"Cancer Immunol Immunother."},{"key":"9464_CR19","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00277-010-0931-3","volume":"89","author":"D-H Yang","year":"2010","unstructured":"Yang D-H, Kim M-H, Hong CY, et al. Alpha-type 1-polarized dendritic cells loaded with apoptotic allogeneic myeloma cell line induce strong CTL responses against autologous myeloma cells. Ann Hematol. 2010;89:795\u2013801. https:\/\/doi.org\/10.1007\/s00277-010-0931-3","journal-title":"Ann Hematol."},{"key":"9464_CR20","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1200\/JCO.2010.30.7744","volume":"29","author":"H Okada","year":"2011","unstructured":"Okada H, Kalinski P, Ueda R, et al. Induction of CD8+\u2009T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol. 2011;29:330\u20136. https:\/\/doi.org\/10.1200\/JCO.2010.30.7744","journal-title":"J Clin Oncol."},{"key":"9464_CR21","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/pros.23194","volume":"76","author":"R Muthuswamy","year":"2016","unstructured":"Muthuswamy R, Corman JM, Dahl K, et al. Functional reprogramming of human prostate cancer to promote local attraction of effector CD8(+) T cells. Prostate. 2016;76:1095\u2013105. https:\/\/doi.org\/10.1002\/pros.23194","journal-title":"Prostate."},{"key":"9464_CR22","doi-asserted-by":"publisher","first-page":"22174","DOI":"10.18632\/oncotarget.7907","volume":"7","author":"L Francis","year":"2016","unstructured":"Francis L, Guo ZS, Liu Z, et al. Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer. Oncotarget. 2016;7:22174\u201385. https:\/\/doi.org\/10.18632\/oncotarget.7907","journal-title":"Oncotarget."},{"key":"9464_CR23","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/mt.2010.312","volume":"19","author":"J Li","year":"2011","unstructured":"Li J, O\u2019Malley M, Urban J, et al. Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Mol Ther. 2011;19:650\u20137. https:\/\/doi.org\/10.1038\/mt.2010.312","journal-title":"Mol Ther."},{"key":"9464_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40425-015-0050-8","volume":"3","author":"R Muthuswamy","year":"2015","unstructured":"Muthuswamy R, Wang L, Pitteroff J, et al. Combination of IFNalpha and poly-I:C reprograms bladder cancer microenvironment for enhanced CTL attraction. J Immunother Cancer. 2015;3:6. https:\/\/doi.org\/10.1186\/s40425-015-0050-8","journal-title":"J Immunother Cancer."},{"key":"9464_CR25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1158\/2326-6066.CIR-15-0157","volume":"4","author":"JL Wong","year":"2016","unstructured":"Wong JL, Obermajer N, Odunsi K, et al. Synergistic COX2 induction by IFNgamma and TNFalpha self-limits type-1 immunity in the human tumor microenvironment. Cancer Immunol Res. 2016;4:303\u201311. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0157","journal-title":"Cancer Immunol Res."},{"key":"9464_CR26","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s00262-010-0876-3","volume":"59","author":"X Zhu","year":"2010","unstructured":"Zhu X, Fallert-Junecko BA, Fujita M, et al. Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners. Cancer Immunol Immunother. 2010;59:1401\u20139. https:\/\/doi.org\/10.1007\/s00262-010-0876-3","journal-title":"Cancer Immunol Immunother."},{"key":"9464_CR27","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1158\/0008-5472.CAN-11-4136","volume":"72","author":"R Muthuswamy","year":"2012","unstructured":"Muthuswamy R, Berk E, Junecko BF. NF-\u03baB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Res. 2012;72:3735\u201343.","journal-title":"Cancer Res."},{"key":"9464_CR28","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.4049\/jimmunol.162.6.3231","volume":"162","author":"P Kalinski","year":"1999","unstructured":"Kalinski P, Schuitemaker JH, Hilkens CM, et al. Final maturation of dendritic cells is associated with impaired responsiveness to. J Immunol. 1999;162:3231\u20136","journal-title":"J Immunol."},{"key":"9464_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/CJI.0b013e318158fce0","volume":"31","author":"LH Butterfield","year":"2008","unstructured":"Butterfield LH, Gooding W, Whiteside TL. Development of a potency assay for human dendritic cells: IL-12p70 production. J Immunother. 2008;31:89\u2013100. https:\/\/doi.org\/10.1097\/CJI.0b013e318158fce0","journal-title":"J Immunother."},{"key":"9464_CR30","doi-asserted-by":"publisher","first-page":"4338","DOI":"10.1245\/s10434-016-5412-z","volume":"23","author":"M Radomski","year":"2016","unstructured":"Radomski M, Pai RK, Shuai Y, et al. Curative surgical resection as a component of multimodality therapy for peritoneal metastases from goblet cell carcinoids. Ann Surg Oncol. 2016;23:4338\u201343. https:\/\/doi.org\/10.1245\/s10434-016-5412-z","journal-title":"Ann Surg Oncol."},{"key":"9464_CR31","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1245\/s10434-015-5037-7","volume":"23","author":"PL Wagner","year":"2016","unstructured":"Wagner PL, Austin F, Zenati M, et al. Oncologic risk stratification following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal carcinomatosis. Ann Surg Oncol. 2016;23:1587\u201393. https:\/\/doi.org\/10.1245\/s10434-015-5037-7","journal-title":"Ann Surg Oncol."},{"key":"9464_CR32","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/1479-5876-11-149","volume":"11","author":"LE Kandalaft","year":"2013","unstructured":"Kandalaft LE, Chiang CL, Tanyi J, et al. A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. J Transl Med. 2013;11:149. https:\/\/doi.org\/10.1186\/1479-5876-11-149","journal-title":"J Transl Med."},{"key":"9464_CR33","first-page":"4272","volume":"7","author":"Y-Q Ai","year":"2014","unstructured":"Ai Y-Q, Cai K, Hu J-H, et al. The clinical effects of dendritic cell vaccines combined with cytokine-induced killer cells intraperitoneal injected on patients with malignant ascites. Int J Clin Exp Med. 2014;7:4272\u201381","journal-title":"Int J Clin Exp Med."},{"key":"9464_CR34","doi-asserted-by":"publisher","first-page":"591","DOI":"10.4049\/jimmunol.0902062","volume":"184","author":"PB Watchmaker","year":"2010","unstructured":"Watchmaker PB, Berk E, Muthuswamy R, et al. Independent regulation of chemokine responsiveness and cytolytic function versus CD8+\u2009T cell expansion by dendritic cells. J Immunol. 2010;184:591\u20137. https:\/\/doi.org\/10.4049\/jimmunol.0902062","journal-title":"J Immunol."},{"key":"9464_CR35","doi-asserted-by":"publisher","unstructured":"Zeytin HE, Patel AC, Rogers CJ, et al. Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg\/MIN mice. Cancer Res. 2004;64:3668\u201378. https:\/\/doi.org\/10.1158\/0008-5472.CAN-03-3878","DOI":"10.1158\/0008-5472.CAN-03-3878"},{"key":"9464_CR36","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1084\/jem.181.5.1887","volume":"181","author":"F Randow","year":"1995","unstructured":"Randow F, Syrbe U, Meisel C, et al. Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor beta. J Exp Med. 1995;181:1887\u201392.","journal-title":"J Exp Med."},{"key":"9464_CR37","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/nri2711","volume":"10","author":"M Saraiva","year":"2010","unstructured":"Saraiva M, O\u2019Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010;10:170\u201381. https:\/\/doi.org\/10.1038\/nri2711.","journal-title":"Nat Rev Immunol."},{"key":"9464_CR38","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1146\/annurev-immunol-031210-101312","volume":"29","author":"W Ouyang","year":"2011","unstructured":"Ouyang W, Rutz S, Crellin NK, et al. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol. 2011;29:71\u2013109. https:\/\/doi.org\/10.1146\/annurev-immunol-031210-101312","journal-title":"Annu Rev Immunol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-09464-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-020-09464-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-09464-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T23:01:18Z","timestamp":1697497278000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-020-09464-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,5]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["9464"],"URL":"https:\/\/doi.org\/10.1245\/s10434-020-09464-9","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,5]]},"assertion":[{"value":"18 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Pawel Kalinski has received a Grant from AIM (previously Hemispherx) to support the trial of Ampligen in patients with COVID-19. This latest development occurred after preparation of this manuscript. Rajesh Ramanathan, Haroon Choudry, Heather Jones, Mark Girgis, William Gooding, and David L. Bartlett have no disclosures to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}